This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
The article, "New Treatment for Ulcerative Colitis," by Louis W. Granirer in The Journal, Sept. 26, page 110, is of interest to us because of our experience with phenylbutazone in treating patients with this disease. Our negative results, obtained early in 1958, acquire pertinence in view of Dr. Granirer's report. We treated six patients with ulcerative colitis during acute exacerbations of moderate severity but without complications. In two patients the onset was recent; they had received no previous treatment. Phenylbutazone was the sole drug given, moderate dietary limitation being the only other therapy (except in one patient who had been receiving small doses of prednisone and antispasmodics, without relief, and who continued to take these drugs). The dosage of phenylbutazone was 300 to 600 mg. daily for one week. The response was evaluated by the proctoscopic appearance before and after treatment as well as by symptoms. Only
Hershenson LM, Hershenson MA. TREATMENT OF ULCERATIVE COLITIS. JAMA. 1959;171(12):1728–1729. doi:10.1001/jama.1959.03010300102026
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: